Altogether, we propose a model in which DYRK1A inhibition leads to accumulation of the cancer cells in the G1/S phase of the cell cycle, delaying/preventing their entry to G2/M, ultimately leading to suppression in cell growth and reduction of the tumor burden in preclinical models of colon and breast cancers. This evidence concerns the gene DYRK1A and breast cancer.